A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...

Mary Bird Perkins Cancer Center has become the first facility in the region to offer a new blood cancer treatment in an ...

Eight children with severe autoimmune diseases who did not respond to conventional therapies were able to completely stop ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...